University of Limerick Institutional Repository

Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study

DSpace Repository

Show simple item record

dc.contributor.author Kieran, Jennifer Ann
dc.contributor.author Norris, Suzanne
dc.contributor.author O'Leary, Aisling
dc.contributor.author Walsh, Cathal Dominic
dc.contributor.author Merriman, Raphael
dc.contributor.author Houlihan, D.
dc.contributor.author McCormick, Aiden
dc.contributor.author McKiernan, Susan
dc.contributor.author Bergin, Colm
dc.contributor.author Barry, Michael
dc.date.accessioned 2016-02-26T16:12:21Z
dc.date.available 2016-02-26T16:12:21Z
dc.date.issued 2015
dc.identifier.citation Kieran, JA,Norris, S,O'Leary, A,Walsh, C,Merriman, R,Houlihan, D,McCormick, PA,McKiernan, S,Bergin, C,Barry, M (2015) 'Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study'. Bmc Infectious Diseases, 15 . en_US
dc.identifier.uri http://hdl.handle.net/10344/4919
dc.description peer-reviewed en_US
dc.description.abstract Background: Recent advances in Hepatitis C therapeutics offer the possibility of cure but will be expensive. The cost of treatment may be partially offset by the avoidance of advanced liver disease. We performed a micro-costing study of the ambulatory healthcare utilisation of patients with Hepatitis C supplemented with inpatient diagnosis related group costs.Methods: The staff utilisation costs associated with a Hepatitis C ambulatory visit were measured and combined with the costs of investigations to establish a mean cost per consultation. An annualised estimate of cost was produced by multiplying this by the number of consultations accessed, stratified by degree of liver impairment. Inpatient costs were established by identifying the number of inpatient episodes and multiplying by Irish diagnosis related group costs. Non-parametric bootstrapping was performed to derive mean and 95% CI values.Results: Two hundred and twenty-five patients were identified. The cost of an outpatient medical review was (sic) 136 ((sic)3.60 SD). The cost of a Hepatitis C nursing review was (sic) 128 ((sic)7.30 SD). The annual mean costs of care were as follows (95% CI): Mild (sic) 398 ((sic) 336, (sic) 482), Moderate (sic) 417((sic) 335, (sic) 503), Compensated cirrhosis (sic) 1790 ((sic) 990, (sic) 3164), Decompensated cirrhosis (sic) 8302 ((sic) 3945, (sic) 14,637), Transplantation Year 1 (sic) 137,176 ((sic) 136,024, (sic) 138,306), Transplantation after Year 1 (sic) 5337 ((sic) 4942, (sic) 5799), Hepatocellular carcinoma (sic)21,992 ((sic)15,222, (sic)29,467), Sustained virological response (sic)44 ((sic)16, (sic)73).Conclusions: The direct medical cost associated with Hepatitis C care in Ireland is substantial and increases exponentially with progression of liver disease. The follow-up costs of patients with a sustained virological response in this cohort were low in comparison to patients with chronic infection. en_US
dc.language.iso eng en_US
dc.publisher BioMed Central en_US
dc.relation.ispartofseries BMC Infectious Diseases;15:471
dc.subject Ireland en_US
dc.subject health economics en_US
dc.subject direct medical cost en_US
dc.subject hepatitis C en_US
dc.title Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study en_US
dc.type info:eu-repo/semantics/article en_US
dc.type.supercollection all_ul_research en_US
dc.type.supercollection ul_published_reviewed en_US
dc.date.updated 2016-02-26T15:59:18Z
dc.description.version PUBLISHED
dc.identifier.doi 10.1186/s12879-015-1208-1
dc.rights.accessrights info:eu-repo/semantics/openAccess en_US
dc.internal.rssid 1617261
dc.internal.copyrightchecked Yes
dc.description.status peer-reviewed


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ULIR


Browse

My Account

Statistics